These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 14755031)
1. The potential epidemiological impact of a genital herpes vaccine for women. Garnett GP; Dubin G; Slaoui M; Darcis T Sex Transm Infect; 2004 Feb; 80(1):24-9. PubMed ID: 14755031 [TBL] [Abstract][Full Text] [Related]
2. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens. Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292 [TBL] [Abstract][Full Text] [Related]
3. Epidemiological impact of a genital herpes type 2 vaccine for young females. Lou Y; Qesmi R; Wang Q; Steben M; Wu J; Heffernan JM PLoS One; 2012; 7(10):e46027. PubMed ID: 23071536 [TBL] [Abstract][Full Text] [Related]
4. Review of mathematical models of HSV-2 vaccination: Implications for vaccine development. Spicknall IH; Looker KJ; Gottlieb SL; Chesson HW; Schiffer JT; Elmes J; Boily MC Vaccine; 2019 Nov; 37(50):7396-7407. PubMed ID: 29625767 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness and efficiency of imperfect therapeutic HSV-2 vaccines. Schwartz EJ; Bodine EN; Blower S Hum Vaccin; 2007; 3(6):231-8. PubMed ID: 17881889 [TBL] [Abstract][Full Text] [Related]
6. Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2. Alsallaq RA; Schiffer JT; Longini IM; Wald A; Corey L; Abu-Raddad LJ Sex Transm Dis; 2010 May; 37(5):290-7. PubMed ID: 20351622 [TBL] [Abstract][Full Text] [Related]
8. Herpes simplex virus type 2 infection in young adult women: risk factors for infection and frequency of viral shedding. Fife KH; Williams JA; Thomas AL; Ofner S; Katz BP; Fortenberry JD Sex Transm Dis; 2010 Apr; 37(4):248-52. PubMed ID: 20216477 [TBL] [Abstract][Full Text] [Related]
9. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. Bourne N; Milligan GN; Stanberry LR; Stegall R; Pyles RB J Infect Dis; 2005 Dec; 192(12):2117-23. PubMed ID: 16288376 [TBL] [Abstract][Full Text] [Related]
15. Reducing the risk of transmitting genital herpes: advances in understanding and therapy. Leone P Curr Med Res Opin; 2005 Oct; 21(10):1577-82. PubMed ID: 16238897 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs. Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802 [TBL] [Abstract][Full Text] [Related]
17. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Stanberry LR Herpes; 2004 Aug; 11 Suppl 3():161A-169A. PubMed ID: 15319086 [TBL] [Abstract][Full Text] [Related]